Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 18/20 | 0.59 |
| ▸ | TAB1 | Q15750 | 18/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18238757 | 1.00 | MAP3K7 (0.59) | MAP3K7TAB1MTNR1AMTNR1BMEN1 | |
| SCHEMBL18238764 | 0.92 | MAP3K7 (0.60) | MAP3K7TAB1MTNR1AMTNR1BMEN1 | |
| SCHEMBL16948727 | 0.92 | MAP3K7 (0.60) | MAP3K7TAB1MTNR1AMTNR1BMEN1 | |
| SCHEMBL16932974 | 0.81 | MAP3K7 (0.58) | MAP3K7TAB1MTNR1AMTNR1B | |
| SCHEMBL16932976 | 0.81 | MAP3K7 (0.58) | MAP3K7TAB1MTNR1AMTNR1B | |
| SCHEMBL18238366 | 0.80 | MAP3K7 (0.54) | MAP3K7TAB1 | |
| SCHEMBL16945169 | 0.80 | MAP3K7 (0.54) | MAP3K7TAB1 | |
| SCHEMBL18238387 | 0.80 | MAP3K7 (0.51) | MAP3K7TAB1MTNR1AMTNR1B | |
| SCHEMBL16948719 | 0.80 | MAP3K7 (0.51) | MAP3K7TAB1MTNR1AMTNR1B | |
| SCHEMBL18238176 | 0.80 | MAP3K7 (0.48) | MAP3K7TAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | TPMT, MALT1, IRAK4 | MAP3K7 152/4885TAB1 861/4885MTNR1A 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.